AMENDMENTS TO THE SPECIFICATION

Please add the following paragraph before the first paragraph on page 1:

This is a national stage application and claims the benefit of PCT/CN2003/001154, filed on December 31, 2003, which in turn claims the priority of Chinese application serial No. CN 03114718.6, filed on January 3, 2003.

Please amend the paragraph starting on page 2, line 33 (corresponds to the published US application No. 2006/0189521, paragraph [0014]) as follows:

In the third aspect, this invention provides a pharmaceutical composition, which comprises a safe and effective amount of antagonists of hLRTM4 protein, wherein the antagonists are selected from the group consisting of: (i) an antisense polynucleotide to hLRTM4 , wherein the polynucleotide has the antisense nucleotide sequence as shown in SEQ ID NO: 1 and has a length of 15-625 [[bp]] bases, and/or (ii) a specific antibody against hLRTM4, as well as a pharmaceutically acceptable vehicle, diluent or carrier.

Please amend the paragraphs starting on page 3, line 4 (correspond to the published US application No. 2006/0189521, paragraphs [0017] and [0018]) as follows:

In the fourth aspect, the invention provides a use of antagonist to hLRTM4, wherein the antagonist is selected from:(i) an antisense polynucleotide to hLRTM4, wherein the polynucleotide has the nucleotide sequence as shown in SEQ ID NO: 1 and has a length of 15-

625 [[bp]] bases; (ii) a small interfering double-strand RNA of hLRTM4, wherein the RNA has the nucleotide sequence as shown in SEQ ID NO:1 and has a length of 17-23 bp and a 3'-terminal dtdt sequence; and/or (iii) a specific antibody against hLRTM4. These antagonists are used to prepare drugs for treatment of hepatocellular carcinoma.

Preferably, the antagonists are antisense polynucleotides to hLRTM4, wherein the polynucleotides has the nucleotide sequence as shown in SEQ ID NO: 1 and has a length of 15-625 [[bp]] bases.